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Abstract
Study Design: Broad narrative review.
Objective: To review and summarize the current literature on guidelines, outcomes, techniques and indications surrounding
multiple modalities of minimizing blood loss in spine surgery.
Methods: A thorough review of peer-reviewed literature was performed on the guidelines, outcomes, techniques, and indi-
cations for multiple modalities of minimizing blood loss in spine surgery.
Results: There is a large body of literature that provides a consensus on guidelines regarding the appropriate timing of dis-
continuation of anticoagulation, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and herbal supplements prior to surgery.
Additionally, there is a more heterogenous discussion the utility of preoperative autologous blood donation facilitated by ery-
thropoietin and iron supplementation for healthy patients slated for procedures with high anticipated blood loss and for whom
allogeneic transfusion is likely. Intraoperative maneuvers available to minimize blood loss include positioning and maintaining nor-
mothermia. Tranexamic acid (TXA), bipolar sealer electrocautery, and topical hemostatic agents, and hypotensive anesthesia (mean
arterial pressure (MAP) <65 mm Hg) should be strongly considered in cases with larger exposures and higher anticipated blood loss.
There is strong level 1 evidence for the use of TXA in spine surgery as it reduces the overall blood loss and transfusion requirements.
Conclusion: As the volume and complexity of spinal procedures rise, intraoperative blood loss management has become a
pivotal topic of research within the field. There are many tools for minimizing blood loss in patients undergoing spine surgery. The
current literature supports combining techniques to use a cost- effective multimodal approach to minimize blood loss in the
perioperative period.
Keywords
intraoperative, blood, loss, transfusions, NSAIDs, aspirin, topical, hemostatic, agents, donation
Introduction
Over the past few decades, the number of spinal procedures
performed in the United States has increased dramatically, with
growth exceeding 200% since the 1990s.1-4 As the volume and
complexity of spinal procedures rise, intraoperative blood loss
management has become a pivotal topic of research within the
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field.5-7 Many spinal procedures are associated with substantial
blood loss. Notable are revision surgeries to treat deformity,
which also have the highest incidence of postoperative
transfusion, ranging from 8% to 30%.8-10 Certain patient char-
acteristics, namely advanced age, higher body mass index
(BMI), greater surgical complexity, and longer fusion constructs
are all associated with more extensive blood loss.6
Transfusions—the traditional answer to clinically relevant
blood loss—are themselves associated with a myriad of com-
plications, including the transmission of bloodborne infection,
immunologic cross-reactions, thromboembolic events, and
immunosuppression.11-13 These complications can lead to lon-
ger hospital stays, increased direct costs, and higher inpatient
mortality.5,14,15 To this end, postoperative transfusion has been
demonstrated by several recent, large retrospective reviews in
spine and nonspine population to increase perioperative mor-
tality, complication rate, and overall care costs.11,16-20 Among
the most concerning complications include significant fluid
shifts capable of damaging the heart, lung, and kidneys, such
as circulatory overload, transfusion-related acute lung injury,
and acute kidney injury.
Owing to this significant side-effect profile, it is incumbent
upon the practicing spine surgeon to possess in their armamen-
tarium those interventions capable of reducing intraoperative
blood loss and transfusion needs. Here, we provide a narrative
review of the recent evidence, highlighting both the preopera-
tive and intraoperative techniques demonstrated to best reduce
perioperative blood loss in spine surgery.
Preoperative Prevention
More than 90% of aged Americans currently use one or more
prescription medications, over-the-counter medications, or diet-
ary supplements.21 Many of these either directly or indirectly
affect the intraoperative bleeding risk through inhibition of the
coagulation pathways or platelet function. Therefore, a thorough,
timely review of medications prior to elective spine surgery is
recommended to decrease otherwise avoidable blood loss.
Nonsteroidal Anti-Inflammatory Drugs
The most common medications of concern are the nonsteroidal
anti-inflammatory drugs (NSAIDs), including aspirin (acetyl
salicylic acid [ASA]), ibuprofen, naproxen, and celecoxib.
These medications inhibit the cyclo-oxygenase (COX)
enzymes, decreasing the production of thromboxane A2
(TXA2), a key upstream trigger of platelet activation and
aggregation. Despite conventional wisdom recommending
their perioperative discontinuation, there remain no actual
guidelines as to the optimal timing for cessation. Most recom-
mendations are based on the pharmaceutical half-lives of these
drugs, yet there is a lack of high-quality evidence in the field of
spine surgery to suggest the optimal timing of discontinua-
tion.22 Consequently, it is observed that most surgeons agree
to an arbitrarily defined number of days prior to surgery.23 In a
recent survey of the Canadian Spine Society, the majority
agreed that discontinuation of antiplatelet agents 7 days prior
to surgery was one of the most important measures for limiting
intraoperative blood loss, with nearly all members endorsing
routine use of this practice.7
Here, it is worth emphasizing the influence of aspirin on
intraoperative bleeding. With the increased prevalence of cor-
onary vascular disease and the documented ability of regular
aspirin usage to lower the risk for coronary events, aspirin
holds a unique place within the NSAID family. While it is
generally held that aspirin should be discontinued on the same
time frame as other antiplatelet agents, the preponderance of
evidence has failed to demonstrate an appreciable effect on
either blood loss or overall complication rate among patients
undergoing spinal surgery.24-26 Therefore, we provide only a
weak recommendation for its discontinuation in patients with
no reasonable indication for continued use. This may help
decrease postoperative bleeding from the wound site.27
Antiplatelet Agents
Many NSAIDs, aspirin in particular, also function as antiplatelet
agents owing to their ability to impair thromboxane A2 produc-
tion, of chief concern here are P2Y12 antagonists (eg, clopido-
grel, prasugrel, ticagrelor, and ticlopidine). These agents have
elimination half-lives of 6 to 15 hours28 and their discontinuation
is recommended by the vast majority of spine surgeons.23 How-
ever, prior evidence has failed to correlate a significant intrao-
perative bleeding risk with preoperative antiplatelet agent
review. One meta-analysis of 46 studies found that continuing
either aspirin or a P2Y12 antagonist (clopidogrel) during the
perioperative period was not associated with a significant
increase in intraoperative blood loss or transfusion risk.29 Level
II evidence from a nonblinded clinical trial also failed to demon-
strate a difference in blood loss, transfusion rate, or complication
rate between patients taking clopidogrel and controls.30 Because
of this, as well as the presence of inconsistency among guide-
lines on the necessity of perioperative discontinuation of anti-
platelet therapy, we believe it is safe to continue patients on
antiplatelet therapy prior to spine surgery. However, for those
desiring to minimize the risk of massive intraoperative blood
loss, the recommended discontinuation time frames can be found
in Table 1.
Anticoagulants
Unlike NSAIDs, a clear consensus exists on the decision to
discontinue therapeutic anticoagulants preoperatively. War-
farin should be stopped 5 days prior to surgery with a target
international normalized ratio (INR) of 1.4 or less; heparin
bridging therapy can then be implemented to prevent venous
thrombotic events (VTEs) in high-risk patients. Newer antic-
oagulants—direct thrombin inhibitors (eg, dabigatran, argatro-
ban) and Xa inhibitors (eg, apixaban, rivaroxaban)—may be
continued until 3 days prior to surgery due to their shorter half-
lives. Heparin bridging is not as well described after the halting
of these medications, but it may be indicated for patients at
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high risk of thromboembolic events. Work-up with the
CHADS2, CHADS2-VASc (clinical prediction rules for esti-
mating the risk of stroke in patients with nonrheumatic atrial
fibrillation), or HAS-BLED scoring system (developed to
assess 1-year risk of major bleeding in patients taking antic-
oagulants with atrial fibrillation),31 and consultation with
hematology may be considered for these patients (Table 2).
Table 1 provides current guidelines where available on when
to stop specific medications in order to minimize intraoperative
blood loss caused by these medications.
It should be noted that numerous other prescription and non-
prescription medications (eg, multivitamins) can significantly
alter successful coagulation cascade function. Typically, any
anti-inflammatory medication or nutritional supplement can
induce more bleeding. Particularly important are herbal and
dietary supplements, which are used by more than 60% of
Americans36 and commonly missed during medication
reviews.21 Many herbal and dietary supplements have been
associated with increased surgical and postoperative bleeding,
including St John’s wort, garlic, ginseng, saw palmetto, and
fish oil.37-39 We suggest also discontinuing these supplements
prior to planned spine surgery.
Preoperative Autologous Blood Transfusion
and Erythropoietin
Another method proposed to reduce transfusion risks for elective
cases with high anticipated blood loss is preoperative autologous
blood donation (PABD). Though valuable in theory, the evi-
dence supporting this method has been mixed with some studies
reporting decreases in allogeneic transfusion rate by up to
50%,40,41 while others found an increased rate of transfusion and
no difference in outcomes.42 The latter likely reflects the use of
PABD in patients with inadequate compensatory erythropoiesis
between phlebotomy and surgery. To avoid this, we recommend
2 steps. In patients considering PABD, a hemoglobin (Hb) level
should be obtained 3 to 4 weeks prior to surgery; those found to
be anemic (Hb < 11 g/dL) should be dissuaded from PABD or
optimized using erythropoietin and iron supplementation. Simi-
larly, for those pursuing PABD that subsequently demonstrate
signs of PABD-induced anemia, erythropoietin (40 000 units SQ
q7d beginning 4 weeks before surgery) and iron supplements
(FeSO4—325 mg orally thrice a day for 4 weeks before surgery)
can be administered preoperatively.43 Erythropoietin (EPO) sig-
nificantly improves preoperative Hb levels, decreases allogeneic
transfusion requirements, and decreases hospital length of stay.44
However, PABD with preoperative EPO treatment is insufficient
to eliminate the risk of perioperative transfusion and up to 40%
of patients may still require transfusion of one or more units of
allogeneic blood products.45 One should note that EPO use is
considered off-label for patients willing to preoperatively donate
autologous blood; Food and Drug Administration (FDA)
approval is only for those with perioperative hemoglobin levels
between 10 and 13 g/dL who are unwilling to donate blood
preoperatively.46 Consequently, PABD with concomitant EPO
administration may be one strategy for reducing transfusion
requirements. However, the overall recommendation for its use
is based largely on retrospective series from the pediatric defor-
mity literature and may not be applicable to adult patients. This
is especially true for older patients with a lower baseline hema-
tocrit in whom PABD may simply shorten the time to first
transfusion. Additionally, evidence suggests that red cell viabi-
lity and function decrease semilinearly with storage time,47 so it
may be that the extent of red cell degeneration seen during the
preoperative period required for anemia resolution nullifies any
potential benefit. For these reasons, as well as the risk of transfu-
sion reaction secondary to clerical error, the use of PABD has
fallen out of favor over the past 2 decades.
Table 1. Drugs that May Increase Surgical Blood Loss.
Drugs That Should Be Stopped Prior to Surgery
Drug Class Mechanism of Action Drug Names
Minimum Cessation
Timea
NSAIDs Nonselective COX inhibition
*Selective COX 2
Diclofenac, Ibuprofen, Celecoxib* 1 day
Indomethacin, Ketorolac, Etodolac, Sulindac, Naproxen 3 days
Piroxicam 7 days
Aspirinb 7 days
Platelet Inhibitors Irreversible ADP receptor
inhibition
*Reversible
Clopidogrel, Prasugrel 7 days
Ticagrelor* 5 days
Ticlopidine 14 days
Anticoagulants Irreversibly inhibit thrombin Low-molecular-weight heparin 1 day
Unfractionated heparin 4-5 hours
Reversibly inhibit thrombin Dabigatran, Rivaroxaban, Apixaban, Endoxaban 3 days
Vitamin K inhibitor Warfarin 5 daysc
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; COX, cyclo-oxygenase; ADP, adenosine diphosphate.
a Minimum cessation time is based on reducing the risk of intraoperative bleeding.
b Aspirin is also an irreversible platelet inhibitor.
c Must check international normalized ratio of 1.4 or less.
*The asterisk in each section refers to the asterisk in the next column.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Intraoperative Blood Loss Management
Positioning
Appropriate surgical positioning is an underappreciated means
of decreasing intraoperative blood loss. Two considerations
include (1) the relative positions of the surgical site and right
atrium and (2) the intra-abdominal pressure (IAP). For opera-
tions on the lumbar and lower thoracic spine, placing the
patient into a Trendelenburg position can reduce pressure in
the inferior vena cava and consequently decrease bleeding from
the epidural and vertebral venous plexuses; reverse Trendelen-
burg offers similar benefits in cervical procedures.
Appropriate table selection can also help facilitate hemostasis
for requiring prone positioning. Conventional surgical tables
elevate IAP, in turn causing congestion of the epidural venous
plexus—a common source of bleeding.48 To avoid this, a Jack-
son table or a Wilson frame with wide interpad spacing can be
employed, as both allow free suspension of the abdomen,
decreasing IAP and draining blood away from the operative site.
Alternatively, for those centers without this option, adoption of
the jackknife position can reduce IAP and blood loss relative to
standard prone positioning for single level lumbar surgery.49,50
Normothermia
Maintaining core temperature at physiological levels has also
been proposed to reduce blood loss by preventing hypothermia-
induced coagulopathy. The intervention has been only poorly
explored in spine, and several groups have failed to document
an impact of core temperature on blood loss.51,52 Paradoxically, a
meta-analysis of studies from other surgical fields reported even
mild hypothermia to reduce total blood loss and decrease transfu-
sion rates.53 Consequently, the ability of hypothermia to reduce
blood loss is questionable. Perioperative hypothermia is associ-
ated with increased complication rates and mortality though,54
recommending its use for all patients despite its questionable link
to superior hemostatic outcomes. Strategies to prevent hypother-
mia include forced air warming,55 warm socks,56 warmed intra-
venous fluids, and warmed irrigation fluids.57
Hypotensive Anesthesia
Control of the mean arterial pressure (MAP) is a constant dialogue
between surgeon and anesthesiologist. An experienced anesthe-
siologist is often able to strike a balance between the perfusion
demands of vital organs and the surgeon’s request for a low MAP
due to its ability to minimize intraoperative blood loss.
Verma et al58 reported that maintaining a MAP of 65 mm
Hg or less reduced blood loss in deformity cases by 33%.
However, such low MAPs can place the spinal cord at risk of
infarction, especially in cases whereby the spinal cord is pre-
viously injured or already under compression (eg, cervical
spondylotic myelopathy). To prevent this rare, but catastrophic
event, intraoperative neuromonitoring should be used as it
allows for early detection of spinal cord hypoperfusion and can
consequently prevent permanent neurological deficits in the
overwhelming majority of cases.59-61 Hypotensive anesthesia
(MAP 70 mm Hg) may be best reserved for the approach and
instrumentation, where bleeding risk is highest. However, we
recommend maintaining the MAP above 80 mm Hg while
manipulating the neural elements to decrease the likelihood
of ischemic tissue injury. This recommendation is strongest for
patients with increased risk of ischemic complications at base-
line, such as those with peripheral vascular disease, a history of
ischemic events (e.g., stroke), chronic renal failure, or uncon-
trolled diabetes mellitus.62 Overall, we caution against the use
of hypotensive anesthesia when there is risk of neurologic
injury from poor perfusion.
Surgical Approach
The conventional, midline approach is the most common
approach employed for posterior spine surgeries. During dis-
section, care is taken to remain in the avascular plane formed
by the fascial sheaths of the 2 paraspinal muscular bundles.
This is then continued laterally in a subperiosteal dissection
to the facets, past which dissection begets more bleeding. Use
of a Wiltse or paraspinal, muscle-splitting approach has been
suggested to decrease blood loss relative to the midline
approach.63 However, the evidence to support this is relegated
to a single retrospective study. Consequently, we make no
recommendations regarding surgical approach for the reduc-
tion of operative blood loss.
Electrocautery
Since its introduction by Harvey Cushing in the early 1900s,
electrocautery has helped reduce blood loss in neurosurgical
procedures. Conventional techniques have made use of both
monopolar and bipolar cautery for the dissection of soft tissues
and coagulation of bleeding vessels, respectively. In 2008, pre-
market approval was granted for a bipolar sealer device, which
employs radiofrequency energy with concomitant saline irriga-
tion.64 The use of saline helps significantly reduce surgical site
temperatures relative to conventional electrocautery methods,
and consequently may reduce trauma to the dissected tissues.
Multiple studies evaluating this device have demonstrated
reductions in blood loss, operation duration, and transfusion
requirements.65-68 At the same time, these same studies docu-
mented no difference in major complications, hospital length of
stay, or infection rate between patients operated using the bipo-
lar sealer and conventional electrocautery tools.65,66,69,70
Furthermore, a recent meta-analysis by Lan and colleagues69
suggested that the use of a bipolar sealer can reduce operative
times, intraoperative blood loss, and transfusion rates. Last, a
randomized controlled trial published by Wang et al71 on a
series of patients undergoing surgery for degenerative scoliosis
of the lumbar spine also found the use of a bipolar sealer to
reduce operation time, intraoperative blood loss, transfusion
rates, and mean transfusion requirements. Therefore, the use
of a bipolar sealer in larger exposure spine surgery may be
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recommended, with the given that meticulous surgical tech-
niques are employed to control bleeding throughout surgery.
Antifibrinolytics
One of the greatest advancements in minimizing blood loss
during spine surgery has been the introduction of antifibrino-
lytic agents, which in select studies have been demonstrated to
reduce blood loss by up to 50%.72 With the withdrawal of
aprotinin from the US market in 2008, the 2 main antifibri-
nolytics in clinical practice are tranexamic acid (TXA) and
e-aminocaproic acid (EACA). Both compounds are lysine ana-
logues that bind to and prevent activation of plasminogen,
thereby inhibiting fibrinolysis and promoting clot stabilization.
Despite concern that such a procoagulation mechanism of
action may increase the risk of postoperative VTEs, this con-
cern has failed to be borne out in the literature.73,74 The few
FDA-defined contraindications to the use of these agents
include active bleeding (.g, epidural hematoma, subarachnoid
hemorrhage), acquired defective color vision (TXA only),
active intravascular clotting, and known hypersensitivity to the
anti-fibrinolytic acid being used.
e-Aminocaproic Acid
EACA has been found to be a safe and effective antifibrinolytic
agent in spine surgery by multiple prospective randomized
controlled trials (RCTs).75-78 Studies examining its use have
typically employed a loading dose of 100 mg/kg with a main-
tenance dose of 10 mg/kg/h. EACA has been used with both
anterior and posterior surgical approaches for multiple indica-
tions, including pediatric deformity and adult degenerative
pathologies. In the most recent study examining EACA use
in patients operated for adolescent idiopathic scoliosis, EACA
did not lower intraoperative blood loss (EBL), but it was asso-
ciated with significantly decreased total blood loss during the
hospital stay with the treatment group averaging 2400 ml/case
compared to 4100 mL/case in controls (P < .0007).76 It is
speculated that this benefit is derived from the continuous
effect of the EACA infusion, as both intraoperative blood loss
and postoperative drainage were only marginally lower, but the
cumulative effect was statistically significant. Other RCTs all
demonstrated significantly lower estimated blood loss with use
of EACA without any significant difference in complications
between groups.
Tranexamic Acid
TXA has many applications in minimizing blood loss outside
surgery, including leukemia, ocular hemorrhage, trauma with
active hemorrhage, severe hemoptysis, and menorrhagia. TXA
was first introduced surgically in the setting of high-risk car-
diac surgery where it successfully reduced blood transfusion
requirements and cost. It was soon widely adopted in the field
of orthopedic arthroplasty, where it demonstrated similar ben-
efits. TXA is 7 to 10 times more potent than EACA,79 allowing
for commensurately lower doses. On review of the current
literature, the most commonly used regimen employs a loading
dose of 10 mg/kg and maintenance dosing of 1 to 2 mg/kg/h. As
with EACA, class I evidence exists supporting the ability of
TXA to reduce intraoperative blood loss. A recent meta-
analysis of pooled data of 6 randomized placebo-controlled
trials demonstrated a mean decrease in intraoperative blood
loss of 229 mL (P < .00001).74 As with EACA, TXA may
continue to provide hemostatic benefits postoperatively. A pro-
spective randomized, controlled trial of patients undergoing
cervical laminoplasty failed to demonstrate a significant
decrease in intraoperative blood loss with TXA administration.
However, the authors did find total blood loss to be signifi-
cantly lower (P < .01).80 As with the aforementioned studies
assessing its use in thoracolumbar fusion, the authors observed
no significant difference in the VTE rates.73,76,80-85 In the past
year, Lin et al86 published on the use of a high-dose TXA
(50 mg/kg loading dose with a 5 mg/kg/h maintenance infu-
sion), which they found to have complication rates comparable
to historical cohorts using a conventional, low-dose regimen.
Subsequent to this, a prospective, randomized controlled trial
(NCT02053363) has been initiated comparing the two regi-
mens, with results expected in mid-2019.87
Both TXA and EACA are powerful agents in minimizing
blood loss compared with placebo controls. Meta-analysis
pooling results from 12 prospective randomized trials using
either TXA or EACA for adults undergoing spinal fusion74
found antifibrinolytic use to reduce intraoperative blood loss
by a mean of 127 mL (P < .002) and postoperative blood loss
by a mean of 95 mL (P < .009). The use of either antifibrino-
lytic also significantly lowered both the rate of allogeneic red
blood cell (RBC) transfusion (odds ratio ¼ 0.58, P < .04) and
the mean units transfused. Ultimately, the use of these agents
is supported by a high level of evidence (Table 3) and should
be strongly considered in patients undergoing surgery with
high anticipated blood loss. We express no strong preference
between the two antifibrinolytics, although TXA has been
demonstrated to provide superior hemostatic benefits in at
least one recent study.88 From a cost-effectiveness aspect,
TXA may be preferable as it is readily available in generic
form and has been found to be a cost-effective method of
minimizing blood loss.84
Of note, topical and oral formulations of tranexamic acid are
now available. Prior meta-analyses in the joint arthroplasty
literature have demonstrated topical, oral, and intravenous for-
mulations to have similar effects on intraoperative blood loss as
well as similar complication rates.89,90 Similar evidence is not
yet available in the field of spine surgery though.91 Addition-
ally, the use of topical TXA in addition to intravenous TXA
may further decrease blood loss, hemoglobin decrease, and
transfusion requirement.92 Insufficient evidence exists to com-
pare complication profiles in patients with high preoperative
risks of thromboembolic events; however, we speculate that the
topical formulation may be more advantageous for this popu-
lation owing to its more local effects.
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Topical Hemostatic Agents
Although the use of topical hemostatic is ubiquitous, the evi-
dence establishing their ability to minimize blood loss or need
for allogeneic blood transfusion is sparse with only mild evi-
dence supporting their efficacy at reducing blood loss. This may
be due to the tendency to employ them in larger procedures with
higher anticipated blood loss. These agents mechanistically
reduce blood loss through a combination of mechanical
occlusion of bleeding vessels (bone wax, gelatin sponge), plate-
let coagulation (microfibrillar collagen), and/or activation of the
common clotting pathway (flowable matrix). Of note, expand-
able cellulose hemostatic agents should be used with caution in
the absence of posterior spinal elements as they may cause
neural compression.93 All have been deemed relatively safe, and
in the authors’ experience, they are all effective at safely reduc-
ing blood loss.94 A summary of the most commonly employed
agents and their efficacy is presented in Table 4.
Table 3. Antifibrinolytics Literature Review.
Publication Study Design Patients (Controls) Mean DEBL (cm3) Complications Odds Ratio
Tranexamic acid (TXA)
Elwatidy et al, 2008 Double-blinded RCT 64 (32) 273 No data
Wong et al, 2008 Double-blinded RCT 147 (74) 397* 1.01
Farrokhi et al, 2011 Double-blinded RCT 76 (38) 67 No data
Tsutsumimoto et al, 2011 Nonblinded RCT 40 (20) 14.3 No data
Yagi et al, 2012 Retrospective cohort study 106 (63) 466 No complications
Wang et al, 2013 Nonblinded RCT 60 (30) 28.4 No data
Raksakietisak et al, 2015 Double-blinded RCT 78 (39) 250 No data
Colomina et al, 2017 Double-blinded RCT 95 (51) 332* 2.45
Shi et al, 2017 Double-blinded RCT 96 (46) 85* 0.30
e-Aminocaproic acid (EACA)
Urban et al, 2001 Nonblinded RCT 35 (18) No data 0.31
Florintino-Pineda et al, 2004 Double-blinded RCT 36 (17) 99 No complications
Berenholtz et al, 2009 Double-blinded RCT 91 (50) 335 0.37
TXA and EACA
Peters et al, 2015 Double-blinded RCT 32 (13) No data 2.19
Lu et al, 2018 Meta-analysis of 12 RCTs 937 (465) 127 0.62
Abbreviations: EBL, intraoperative estimated blood loss; RCT, randomized controlled trial.
*P < .05.
Table 4. Topical Hemostatic Summary (Source95).




Bone wax Generic Mechanical intercalation within trabecular bone I
Gelatin-based sponge Gelfoam, Gelfilm,
Surgifoam










Forms scaffold for platelet aggregation and clot formation I
Active agents
Antifibrinolytics — Inhibition of plasminogen activation, Antifibrinolytic agent stabilizes fibrin clots A: Supporting
e-Aminocaproic acid Amicar
Tranexamic acid Lysteda
Fibrin sealant Evicel, Tisseel Two components (human fibrinogen and thrombin). Thrombin cleaves the




Floseal, Surgiflo Two components (bovine or porcine gelatin matrix and thrombin powder in
calcium chloride solution) mixed in a syringe, resulting in mechanical
tamponade and fibrin clot formation
A: Supporting
Recombinant activated
factor VII (eptacog a)
NovoSeven,
AryoSeven
Promotes thrombin generation, resulting in formation of a stable fibrin plug. A: Supporting
a Grade A: Good evidence (level I studies with consistent findings) for or against recommending intervention. Grade B: Fair evidence (Level II-III studies with
consistent findings) for or against recommending intervention. Grade C: Conflicting of poor-quality evidence (level IV-V studies) not allowing a recommendation.
Grade I: There is insufficient evidence to make a recommendation.
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Intraoperative Cell Salvage
A final intervention capable of minimizing the effect of blood
loss during spine surgery is the use of intraoperative cell sal-
vage (ICS). ICS works by draining fluid and blood from the
dissection cavity and filtering out clotting factors, platelets, and
other debris to form an RBC-enriched unit that can then be
returned to the patient. The use of this technology has been
most thoroughly reported in the field of pediatric deformity,
where ICS has been demonstrated to reduce the need for allo-
geneic blood transfusion.96,97 One recent study on the use of
ICS in scoliosis surgery showed a significant decrease in the
rate of allogeneic blood transfusion—6% versus 55% in those
not treated with ICS.98
One caveat of ICS is that it requires a minimum blood loss in
order to produce a transfusable unit; the size of the blood loss is
dictated by the size of the transfusion bowl. Because of this
minimum transfusion requirement, the cost-effectiveness of
ICS depends on the expected transfusion volume. In patients
with high expected blood loss, such as those undergoing sur-
gery for adolescent idiopathic scoliosis, ICS has been found to
be cost-neutral compared to allogeneic blood transfusion.99
Most studies have found ICS to have a very low complication
profile, though at least one study has reported acute kidney
injury in the setting of ICS transfusion.100
Viscoelastic Testing: Rotational Thromboelastometry
and Thromboelastography
The ability to monitor the coagulation properties of a patient’s
blood in real time can potentially make a substantial difference
in the overall blood loss and risk of allogeneic transfusion.
Failure to recognize increasing bleeding diathesis can lead to
run-away hemorrhage. Conventional means of assessing a
patient’s coagulation status focus on the use of periodic blood
draws, which are then tested to determine the activated partial
thromboplastin time (aPTT)—a measure of the intrinsic and
common coagulation pathways—and the international normal-
ized ratio (INR)—a means of testing the extrinsic and common
pathways. Unfortunately, these tests are often slow to result and
possibly inaccurate, especially in the operating room.101 Vis-
coelastic methods are an alternative to these that is gaining
attention in spine literature.102-104
Viscoelastic methods describe 2 classes of point-of-care tests
that emulate sluggish venous blood flow in a small sample of
patient blood obtained intraoperatively.105 The size, stiffness,
and time to clot are measured and interpreted to provide an
estimate of the adequacy of the patients clotting ability. Two
variations of this technology—rotational thromboelastometry
(ROTEM) and thromboelastography (TEG)—exist. The tech-
nologies differ slightly in their set-up and required reagents but
have been demonstrated to be similarly accurate in direct com-
parisons.106 Two recent reviews found both technologies were
associated with decreased rates of transfusion of red cells,
plasma, and platelets compared with other means of assessing
a patient’s transfusion needs intraoperatively.107,108
Additionally, Guan et al102 and Naik et al104 have published
their experiences using ROTEM for patients undergoing elective
spine surgery. Naik and colleagues104 reported that the use of
ROTEM significantly decreased intraoperative plasma transfu-
sion requirements and was associated with a cost savings of
nearly $2000 per patient. By comparison, Guan et al102 observed
a significant decrease in total intraoperative red cell, plasma, and
total blood product transfusion volumes. Additionally, the
impact of ROTEM remained significant on multivariate analy-
sis, independent of surgical invasiveness, preoperative INR and
hematocrit, and TXA use. These results have been replicated in
other surgical fields, including pediatric neurosurgery,109 cardiac
surgery,110 and liver transplantation.111
The biggest drawback of viscoelastic testing methods is that
they require additional machinery and training of the anesthesia
personnel. To our knowledge, the ability of the small interval
costs savings to offset these hardware and personnel training
costs has not been evaluated. As a result, we believe insuffi-
cient evidence exists to recommend the use of these interven-
tions at small volume centers. However, we do recommend that
surgeons at high volume centers with viscoelastometry-trained
anesthesia staff, consider using ROTEM or TEG to help reduce
transfusion requirements and total care costs.
Postoperative Drain Use
Postoperative, “hidden” blood loss may also substantially con-
tribute to postoperative anemia and the need for transfusion,
with prior studies suggesting that these losses may account for
40% to 47% of total blood loss.112,113 The use of closed suction
drains postoperatively is one intervention that has been sug-
gested to decrease these hidden losses. The theoretical benefits
of drains derive from the avoidance of neural element compres-
sion and excessive subfascial fluid pressure. Unfortunately, the
same negative pressure changes that mediate these effects may
also increase incisional drainage and surgical site hematoma
formation. For this reason, the current state of spine literature
does not allow for a general recommendation.114,115 However,
we generally place drains for patients undergoing open poster-
ior procedures involving more than 2 levels owing to their
ability to decrease rates of wound infection and return to the
operating room for wound revision.116
Conclusion
Major spine surgery can be associated with significant intrao-
perative blood loss. Factoring in the expected operation dura-
tion, surgical approach/exposure employed, and surgical
complexity is extremely important in planning hemodynamics
perioperatively; every effort should be made to minimize blood
loss and to avoid transfusion (we weakly recommend a thresh-
old of 7-8 g/dL unless symptomatic). Aside from patient coun-
seling, preoperative optimization includes discontinuation of
anticoagulation prior to surgery; the exact timeframe for dis-
continuation is dictated by the elimination half-life of the drug.
Additionally, many surgeons advise discontinuation of aspirin
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and other NSAIDs at least 1 week prior to surgery, though the
evidence substantiating this recommendation is mixed. Finally,
in healthy patients slated for procedures with high anticipated
blood loss and for whom allogeneic transfusion is likely, pre-
operative autologous blood donation may help to reduce the
rates of transfusion. However, when this is pursued, it should
be done early enough to allow resolution of the post-
phlebotomy anemia, which could be facilitated by erythropoie-
tin and iron supplementation.
Intraoperative maneuvers available to minimize blood loss
include positioning to reduce intraabdominal pressure and main-
tenance of normothermia. The use of TXA, bipolar sealer elec-
trocautery, and topical hemostatic agents (eg, oxidized
regenerated cellulose, microfibrillar collagen, gelatin sponges,
flowable agents) should be strongly considered in cases with
larger exposures and higher anticipated blood loss. Hypotensive
anesthesia (MAP <65 mm Hg) can also facilitate lower blood loss,
though we caution against its routine use due to potential cata-
strophic ischemic neural injury. In our opinion, the MAP should
be maintained above 80 mm Hg while manipulating neural ele-
ments to avoid neuromonitoring abnormalities. Finally, cell sal-
vage should be considered in patients with high estimated blood
loss, especially where allogeneic transfusion is not an option (eg,
due to patient beliefs or rare patient blood type).
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